Metropolitan Life Insurance Company (MetLife)’s RAPT Therapeutics RAPT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-198	Closed	-$14.2K	–	1640
2024 Q1	$14.2K	Sell	198 -40	-17%	-$5.56K	﹤0.01%	2014
2023 Q4	$47.2K	Hold	238	–	–	﹤0.01%	1478
2023 Q3	$31.6K	Buy	238 +39	+20%	+$6.37K	﹤0.01%	1654
2023 Q2	$29.7K	Hold	199	–	–	﹤0.01%	1721
2023 Q1	$29.1K	Hold	199	–	–	﹤0.01%	1699
2022 Q4	$31.4K	Hold	199	–	–	﹤0.01%	1762
2022 Q3	$38.2K	Hold	199	–	–	﹤0.01%	1636
2022 Q2	$29K	Buy	199 +42	+27%	+$5.6K	﹤0.01%	1841
2022 Q1	$27.6K	Sell	157 -509	-76%	-$96.1K	﹤0.01%	1932
2021 Q4	$196K	Hold	666	–	–	﹤0.01%	2042
2021 Q3	$165K	Hold	666	–	–	﹤0.01%	2215
2021 Q2	$169K	Buy	+666	New	+$124K	﹤0.01%	2271
2020 Q4	–	Sell	-461	Closed	-$119K	–	2566
2020 Q3	$119K	Hold	461	–	–	﹤0.01%	2119
2020 Q2	$107K	Buy	+461	New	+$71.3K	﹤0.01%	2222

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RAPT Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 198 shares — an estimated $14.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RAPT in Q2 2020 and held it in 14 quarters. The position peaked at $196K in Q4 2021. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 198 RAPT Therapeutics shares in Q2 2024, an estimated $14.2K.
Metropolitan Life Insurance Company (MetLife) first reported a position in RAPT Therapeutics in Q2 2020 and held it in 14 quarters.
Metropolitan Life Insurance Company (MetLife)'s RAPT Therapeutics position peaked at $196K in Q4 2021.
103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.